ALPEGA-GROUP
27.3.2020 13:07:08 CET | Business Wire | Press release
In response to the coronavirus crisis, Teleroute invites transport and logistics companies to join its community free of charge till the end of June.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200327005212/en/
In normal times, more than 200,000 daily freight and vehicle offers are posted on Teleroute . However, the COVID-19 pandemic has led to a drastic increase in the volume of goods required by sectors like retail and pharma. All of this is putting the response capacity of the transport and logistics sector, whose role is key to the management of this crisis, to the test.
For this reason, the Teleroute Freight Exchange , part of the Alpega Group , wants to help alleviate the situation by offering free access to all transport and logistics companies that wish to join its platform, till the end of June and without any contractual obligation to prolong.
About this initiative, Fabrice Douteaud , Chief Operation Officer Freight Exchange, comments: “We feel it is our responsibility to help society in all possible ways during this difficult period. Hence, we are joining the wave of solidarity by significantly enlarging our transport community with these temporary measures and contribute to overcoming the logistic challenges that we are facing with COVID-19. By spreading the word about this initiative, all of us can support in further shaping transport collaboration.”
All the security guarantees offered by Teleroute, such as its Quality Assurance Policy in accepting new members or the recently announced Payment Guarantee , remain unchanged, as the main objective is to continue providing the industry with the best possible collaboration network at a time when cooperation between companies is more necessary than ever. Securing the safety of the platform therefore remains a number one priority.
The freight exchanges were born to achieve greater efficiency in transport and to bring the different actors in the sector together. Now, it is up to all of us to create a stronger transport network that remains united in times like these. #Allinthistogether
About Alpega
The Alpega Group is a leading global logistics software company offering end-to-end solutions that cover all transportation needs, including Transport Management Systems (TMS) and Freight Exchanges. The Transport Management Systems (TMS) software solutions – inet and Transwide– connect companies to a broad network of logistics providers and digitize their complex supply chain management. These systems provide live visibility of incoming and outgoing logistics and seamlessly link truck drivers and logistics providers with shippers. The freight exchanges – Teleroute, Wtransnet, Bursa and 123cargo – serve as marketplaces for matching spot shipments and capacities. TenderEasy, for its part, allows shippers to easily send e-tenders to the carrier community. All of the above solutions can be combined to create more added value for customers. Our user community of 80.000 carriers and shippers and 200.000 members are electronically connected every day to successfully manage critical transport processes of 108.000.000 orders every year. Alpega is present in 80 countries worldwide and employs over 500 people with 31 different nationalities.
For more information, visit www.alpegagroup.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200327005212/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom